396 related articles for article (PubMed ID: 23706759)
1. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
Strain WD; Lukashevich V; Kothny W; Hoellinger MJ; Paldánius PM
Lancet; 2013 Aug; 382(9890):409-416. PubMed ID: 23706759
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
Hong AR; Lee J; Ku EJ; Hwangbo Y; Kim KM; Moon JH; Choi SH; Jang HC; Lim S
Diabetes Res Clin Pract; 2015 Jul; 109(1):141-8. PubMed ID: 26003889
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
5. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Matthews DR; Dejager S; Ahren B; Fonseca V; Ferrannini E; Couturier A; Foley JE; Zinman B
Diabetes Obes Metab; 2010 Sep; 12(9):780-9. PubMed ID: 20649630
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
[TBL] [Abstract][Full Text] [Related]
8. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
Kothny W; Foley J; Kozlovski P; Shao Q; Gallwitz B; Lukashevich V
Diabetes Obes Metab; 2013 Mar; 15(3):252-7. PubMed ID: 23039321
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Goodman M; Thurston H; Penman J
Horm Metab Res; 2009 May; 41(5):368-73. PubMed ID: 19221978
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).
Mathieu C; Barnett AH; Brath H; Conget I; de Castro JJ; Göke R; Márquez Rodriguez E; Nilsson PM; Pagkalos E; Penfornis A; Schaper NC; Wangnoo SK; Kothny W; Bader G
Int J Clin Pract; 2013 Oct; 67(10):947-56. PubMed ID: 23961850
[TBL] [Abstract][Full Text] [Related]
11. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
[TBL] [Abstract][Full Text] [Related]
13. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
Shelbaya S; Rakha S
Curr Med Res Opin; 2017 May; 33(5):797-801. PubMed ID: 28303721
[TBL] [Abstract][Full Text] [Related]
16. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
17. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
Dejager S; Razac S; Foley JE; Schweizer A
Horm Metab Res; 2007 Mar; 39(3):218-23. PubMed ID: 17373638
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
